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Abstract
Objective: Some features of subjects with Prader‐Willi syndrome (PWS) resemble 
those seen in growth hormone deficiency (GHD). Children with PWS are treated with 
growth hormone (GH), which has substantially changed their phenotype. Currently, 
young adults with PWS must discontinue GH after attainment of adult height when 
they do not fulfil the criteria of adult GHD. Limited information is available about the 
prevalence of GHD in adults with PWS. This study aimed to investigate the GH/insu‐
lin‐like growth factor (IGF‐I) axis and the prevalence of GHD in previously GH‐treated 
young adults with PWS.
Design: Cross‐sectional study in 60 young adults with PWS.
Measurements: Serum IGF‐I and IGFBP‐3 levels, GH peak during combined growth 
hormone‐releasing hormone (GHRH)‐arginine stimulation test.
Results: Serum IGF‐I was <−2 standard deviation scores (SDS) in 2 (3%) patients, and 
IGFBP‐3 was within the normal range in all but one patient. Median (IQR) GH peak 
was 17.8 μg/L (12.2; 29.7) [~53.4 mU/L] and below 9 μg/L in 9 (15%) patients. Not 
one patient fulfilled the criteria for adult GHD (GH peak < 9 μg/L and IGF‐I < −2 SDS), 
also when BMI‐dependent criteria were used. A higher BMI and a higher fat mass 
percentage were significantly associated with a lower GH peak. There was no signifi‐
cant difference in GH peak between patients with a deletion or a maternal uniparen‐
tal disomy (mUPD).
Conclusions: In a large group of previously GH‐treated young adults with PWS, ap‐
proximately 1 in 7 exhibited a GH peak <9 μg/L during a GHRH‐arginine test. 
However, none of the patients fulfilled the consensus criteria for adult GHD.
K E Y W O R D S
arginine, growth hormone, growth hormone deficiency, growth hormone‐releasing hormone, 
IGF‐I, Prader‐Willi syndrome
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1  | INTRODUC TION
Prader‐Willi syndrome (PWS) is a rare disorder resulting from the 
lack of expression of the PWS region (q11‐q13) on the paternally 
derived chromosome 15. This is mostly caused by a paternal dele‐
tion or maternal uniparental disomy (mUPD) and in some cases by an 
imprinting centre defect or paternal chromosomal translocation.1,2 
Clinical findings change with age, with infancy being characterized 
by muscular hypotonia and failure to thrive, while short stature, psy‐
chomotor delay, hyperphagia and obesity are more prominent during 
childhood and adulthood.1,3
Some features of people with PWS resemble those seen in 
growth hormone deficiency (GHD), such as short stature and an 
abnormal body composition with a low lean body mass (LBM) and 
an increased fat mass (FM). Long‐term continuous growth hor‐
mone (GH) treatment in children with PWS improves body com‐
position, linear growth, physical strength, cognition and adaptive 
functioning, substantially changing the phenotype of children 
with PWS.4‐9 Currently, young adults with PWS have to stop GH 
treatment after attainment of adult height, when they do not fulfil 
the criteria of adult GHD. Studies have shown that GH treatment 
is beneficial for adults with PWS, with a sustained improvement 
in FM and LBM when GH is continued after attainment of adult 
height, and a deterioration of body composition when GH treat‐
ment is discontinued.10,11
Reduced serum insulin‐like growth factor (IGF‐I) levels and a re‐
duced GH response to provocative stimuli were found in a varying 
percentage of children and adults with PWS.3,12‐18 Most studies in 
adults with PWS have investigated GHD in adults who were not 
treated with GH during childhood and the prevalence of GHD var‐
ied dependent on the diagnostic test and the chosen cut‐off points, 
which were or were not corrected for BMI. This study aimed to 
assess the GH response to a growth hormone releasing hormone 
(GHRH)‐arginine stimulation test in a large sample of young adults 
with PWS who had attained adult height and were previously treated 
with GH during childhood.
2  | METHODS
2.1 | Patients
Inclusion criteria for the present study were (i) genetically con‐
firmed diagnosis of PWS by a positive methylation test, (ii) GH 
treatment during childhood for at least two years and (iii) having 
attained adult height, defined as a height velocity <0.5 cm per 
6 months and epiphyseal closure as demonstrated by a radiograph 
of the left hand and wrist. Exclusion criteria were (i) medication 
to reduce weight or fat or (ii) noncooperative behaviour. Sixty 
subjects were included, who were all on a diet and exercise pro‐
gramme. Written informed consent was obtained from patients and 
their parents or legal representatives. The study protocol was ap‐
proved by the Medical Ethics Committee of the Erasmus University 
Medical Centre, Rotterdam.
2.2 | Design
All participants were followed at the Dutch PWS Reference Centre. 
They were treated with biosynthetic GH (Pfizer Inc) during child‐
hood, administered subcutaneously once daily at bedtime in a dose 
of 1.0 mg/m2/d (≈0.035 mg/kg/d). The GH dose was regularly ad‐
justed based on calculated body surface area and serum IGF‐I levels. 
At attainment of adult height, GH treatment was discontinued for at 
least six weeks prior to performing a standard GH stimulation test 
with growth hormone‐releasing hormone (GHRH) and arginine.19
2.3 | Anthropometry
Standing height was measured using a Harpenden Stadiometer, and 
weight was measured on a calibrated electric scale (Servo Balance 
KA‐20‐150S; Servo Berkel Prior). Height, weight and body mass 
index (BMI) were expressed as standard deviation scores (SDS) using 
growth analyser 4.0 (available at www.growthanalyser.org), adjusting 
for age (18 years) and sex according to Dutch reference values.20,21
2.4 | Body composition
Body composition was assessed by dual‐energy X‐ray absorptiom‐
etry (DXA; Lunar Prodigy; GE Healthcare), within four months of the 
GHRH‐arginine stimulation test in 41 participants. Total fat mass 
(FM; kg) and lean body mass (LBM; kg) were assessed. All scans were 
made on the same machine, with daily quality assurance. The intra‐
assay coefficient of variation (CV) for fat tissue was 0.41%‐0.88% 
and for LBM 1.57%‐4.49%.22 FM was also expressed as percentage 
of total body weight (FM%). LBM was calculated as fat‐free mass 
minus bone mineral content. FM% SDS and LBM SDS were calcu‐
lated according to age‐ and sex‐matched Dutch reference values.23
2.5 | GHRH-arginine test
Growth hormone stimulation tests started at 8.30 am after overnight 
fasting, with the patients recumbent. After an indwelling catheter 
had been placed, each participant received GHRH (1 μg/kg as in‐
travenous bolus at 0 minute, with a maximum dose of 100 μg) and 
arginine (0.5 g/kg during 30 minutes, with a maximum dose of 50 g). 
Blood samples for GH determination were drawn at 0, 15, 30, 45, 
60 and 90 minutes after the intravenous bolus of GHRH. Levels of 
GH, IGF‐I and IGFBP‐3 were measured using the IDS‐iSYS immu‐
noassay system, which is based on chemoluminescence. The intra‐
assay variations were <6.4%, <7.5% and <5.1%, respectively. Levels 
of IGF‐I and IGFBP‐3 were expressed as SDS, adjusting for age and 
gender.24,25
2.6 | Statistical analysis
Statistical analyses were performed with spss 24.0 (SPSS Inc). Data 
were expressed as median (IQR). The GH response to GHRH and 
arginine was assessed by the evaluation of the highest GH plasma 
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concentration, that is the GH peak. GHD in adults was defined as a 
GH peak level after GHRH‐arginine test <9 μg/L in combination with 
a serum IGF‐I SDS level <–2.0 adjusted for age and gender.3,19 We also 
applied the BMI‐dependent cut‐off points for the GHRH‐arginine test: 
a GH peak of <11.5 μg/L if BMI is <25 kg/m2, a GH peak of <8.0 μg/L 
if BMI is 25‐30 kg/m2, and a GH peak of <4.2 μg/L if BMI >30 kg/m2.26
Pearson's correlation coefficients were used to assess relation‐
ships between IGF‐I and GH peak and anthropometric measure‐
ments and body composition variables. Student's t tests were used 




Sixty young adults with PWS (27 males, 33 females) with a median 
(IQR) age of 17.9 (16.3; 19.6) years were included in the current eval‐
uation of GH response to a GHRH‐arginine stimulation test (Table 1). 
GH treatment during childhood was started at a median (IQR) age 
of 6.6 (4.0; 8.8) years. Twenty‐nine young adults had a deletion 
(48.3%), 25 a maternal uniparental disomy (mUPD; 41.7%) and five a 
paternal translocation (8.3%). One patient refused further investiga‐
tion of the genetic subtype.
Twenty‐nine patients were receiving sex steroid replacement ther‐
apy (SSRT), and seven had spontaneous oestrogen or testosterone 
levels within the normal range. The remaining 24 subjects were consid‐
ered hypogonadal, but were not receiving SSRT at time of evaluation.
3.2 | GH response to GHRH-arginine test
Table 2 and Figure 1 show the results of the GHRH‐arginine tests 
and serum IGF‐I and IGFBP‐3 levels. Median (IQR) GH peak was 
17.8 μg/L (12.2; 29.7) [~53.4 mU/L]. Median (IQR) serum IGF‐I was 
−0.4 (−1.1; 0.4) SDS and IGFBP‐3 1.6 (1.0; 2.2) SDS.
Serum IGF‐I was <−2 SDS in two (3%) patients, and IGFBP‐3 was 
within the normal range in all but one participant. Nine participants 
had a peak GH level <9 μg/L (15%) during the GHRH‐arginine test. 
None of these patients also had an IGF‐I level <−2.0 SDS. When 
BMI‐dependent criteria were used, nine participants had a GH peak 
below the cut‐off (15%). Again, none of these patients also had an 
IGF‐I <−2.0 SDS. Thus, not one of our patients fulfilled the criteria 
of adult GHD.
Growth hormone peak was not significantly different between 
participants with a deletion and those with a mUPD (P = 0.99) or 
between males and females (P = 0.41). There was also no signif‐
icant difference in GH peak between hypogonadal patients who 
were not receiving SSRT and patients who were receiving SSRT 
or had spontaneous oestrogen and testosterone levels within the 
normal range at the time of the GHRH‐arginine stimulation test 
(P = 0.67).
3.3 | Correlation analyses
A higher BMI SDS and a higher FM% SDS were significantly as‐
sociated with a lower GH peak (r = −0.46, P < 0.01 and r = −0.43, 
P < 0.01, resp.). The GH peak did neither correlate with age or waist‐
hip ratio (both P > 0.13), nor with IGF‐I SDS (r = 0.01, P = 0.93). There 
was no significant correlation between IGF‐I SDS and BMI SDS or 
FM% SDS (r = −0.14, P = 0.94 and r = 0.008, P = 0.96, resp.).
3.4 | IGF-I at start of GH treatment 
during childhood
Clinical characteristics and median serum IGF‐I and IGFBP‐3 levels 
of the young adults at start of GH treatment during childhood are 
shown in Tables 1 and 2, respectively. Before starting GH treatment 
at a median age of 6.6 years, 18 children (30%) had an IGF‐I <−2 SDS. 
Serum IGF‐I was unknown in eight children (13.3%). Of the 18 chil‐
dren with an IGF‐I <−2 SDS at start of GH, only two had an IGF‐I <−2 
 Adult height During childhooda 
Age (y) 17.9 (16.3; 19.6) 6.6 (4.0; 8.8)
Male/Female (n) 27/33 27/33
Genetic subtype
Deletion/mUPD/translocation/unknown 29/25/5/1 29/25/5/1
Height for age (SDS) −1.0 (−1.7; −0.3) −2.2 (−3.0; −1.8)
BMI 24.2 (21.1; 27.9) 17.9 (16.3; 19.4)
BMI for age (SDS) 1.1 (−0.2; 1.9) −0.6 (−1.1; 0.1)
FM% 40.5 (35.7; 47.5) 34.2 (28.9; 38.3)
FM% SDS 2.3 (1.8; 2.6) 2.3 (2.1; 2.6)
LBM SDS −2.3 (−3.1; −1.2) −2.5 (−2.8; −2.0)
Note. Data expressed as median (IQR). FM and LBM at adult height were assessed in 41 individuals 
and in 38 individuals during childhood.
Abbreviations: BMI, body mass index; FM%, fat mass percentage; LBM, lean body mass; mUPD, 
maternal uniparental disomy; SDS, standard deviation scores.
aGH naïve before start of GH treatment. 
TA B L E  1   Clinical characteristics at 
adult height and during childhood
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SDS after cessation of GH. None of them had a GH peak <9 μg/L 
during the GHRH‐arginine test. So, none of the young adults with an 
IGF‐I <−2 at start of GH during childhood fulfilled the criteria of adult 
GHD after cessation of GH treatment at attainment of adult height, 
also when BMI‐dependent cut‐off values were used.
Before start of GH treatment, there was no significant difference 
in height, BMI, FM% and LBM SDS between children with an IGF‐I 
<−2 SDS and >−2 SDS (all P > 0.34).
4  | DISCUSSION
This study investigated the GH/IGF‐I axis and the prevalence of GHD 
in a large group of 60 young adults with PWS, who were treated 
with GH for more than 10 years during childhood until attainment 
of adult height. Against expectations, our data show that none of 
the patients had adult GHD according to the consensus criteria, also 
when BMI was taken into account. Results were variable, with some 
patients having a low serum IGF‐I and normal GH peak, and others a 
normal serum IGF‐I and low GH peak. In most countries, adults with 
PWS cannot be treated with GH after attainment of adult height, if 
they do not fulfil the consensus criteria for adult GHD.
Patients with PWS have several clinical features that resemble 
those seen in GHD, including short stature and an abnormal body 
composition with an increased fat mass and decreased muscle 
mass.1 Both children and adults with PWS respond favourably to 
GH treatment, with a complete normalization of stature in children, 
an increase in serum IGF‐I and IGFBP‐3 levels and a significant im‐
provement in body composition, without safety concerns.4,10,11 It 
was generally believed that young adults with PWS would have GHD 
and could continue GH treatment after attainment of adult height. 
However, completely unexpected, none of the 60 young adults ful‐
filled the current consensus criteria for the diagnosis of adult GHD. 
Only two of our patients (3%) had an IGF‐I level <−2 SDS, and none 
of them had a GH peak <9 μg/L. Thus, a decreased IGF‐I level was 
not accompanied by a low GH peak during provocative testing. On 
the other hand, nine (15%) patients had a low GH peak, but com‐
pletely normal serum IGF‐I levels.
The reported prevalence of GHD in children and adults with 
PWS varies. According to a review by Burman et al,12 40%‐100% 
of children with PWS fulfilled the criteria for GHD, depending 
on the stimulation test used. Three recent studies investigated 
the prevalence of GHD in mostly GH‐naïve adult PWS patients, 
aged 16‐43 years, by performing GHRH‐arginine tests.3,16,27 Two 
of these studies, in 15 and 41 adult patients, also reported a low 
prevalence of GHD, with only one (8%) and six (15%) of the partici‐
pants fulfilling the diagnostic criteria for GHD according to BMI‐de‐
pendent cut‐off points, respectively.3,27 In contrast, Grugni et al16 
described severe GHD in 16 out of 37 adults with PWS (43.5%). 
However, mean BMI of their study group was 45.2 kg/m2, which is 
much higher than the median BMI of 24.2 kg/m2 in our study and 
the reported median BMI of approximately 27 kg/m2 in the other 
F I G U R E  1   Growth hormone (GH) Peak 
and IGF‐I SDS in 60 young adults with 
PWS. GH peak during GHRH‐arginine test 
according to age in young adults with 
PWS. The dashed line shows the cut‐off 
value for GHD (9 μg/L). The open circles 
represent patients with an IGF‐I SDS <−2 
SDS, the black circles >−2 SDS. GHD, 
growth hormone deficiency; GHRH, 
growth hormone‐releasing hormone; 
IGF‐I, Insulin‐like growth factor; SDS, 
standard deviation scores
TA B L E  2   GH response to GHRH‐arginine stimulation test
 At adult height During childhooda 
IGF‐I (nmol/L) 32.4 (21.3; 39.6) 7.5 (5.2; 12.7)
IGF‐I SDS −0.4 (−1.1; 0.4) −1.7 (−2.2; −0.9)
IGFBP‐3 (mg/L) 4.7 (4.0; 5.7) 1.2 (0.9; 1.5)
IGFBP‐3 SDS 1.6 (1.0; 2.2) −2.0 (−3.1; −1.4)
GH peak (μg/L) 17.8 (12.2; 29.7) —
Time to GH peak (min) 45.0 (30.0; 60.0) —
Note. Data expressed as median (IQR).
Abbreviations: GH, growth hormone; IGFBP‐3, Insulin‐like growth 
factor‐binding protein 3; IGF‐I, Insulin‐like growth factor; SDS, standard 
deviation scores.
aGH naïve before start of GH treatment. 
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two studies.3,27 Even though BMI‐dependent cut‐off points were 
used, a mean BMI of 45.2 kg/m2 is so far above the upper limit 
of 30 kg/m2 that there is an increased likelihood of a blunted GH 
 response to a GHRH‐arginine test. Conceivably, the current BMI‐
dependent cut‐off points may not be suitable for patients with very 
severe obesity.28 Also, in contrast to the adults investigated in the 
aforementioned studies, all young adults participating in our study 
were treated with GH from a median age of 6.6 years until attain‐
ment of adult height.
The GHRH‐arginine test is reported as reliable as the insulin tol‐
erance test (ITT) for (re)testing patients treated with GH during child‐
hood.19,29 Given the increased risk of severe side effects during an 
ITT and the higher burden of this test, we chose to perform GHRH‐
arginine instead of insulin tolerance tests. There is discussion about 
the appropriate cut‐off values for GH peak during GHRH‐arginine 
tests. A cut‐off value of 15.9 μg/L for severe adult GHD has been 
proposed for retesting late adolescents with childhood‐onset GHD. 
However, due to the small number of overweight patients, a separate 
cut‐off for adolescents with a high BMI was not obtained.30 One‐
third of our patients had a BMI >25 kg/m2, and the cut‐off values, 
as proposed by Dreismann et al,26 are therefore not applicable to 
our patients with PWS. We decided to use the BMI‐adjusted adult 
cut‐off values instead.
Two studies in young children with PWS described a low GH 
peak after clonidine or arginine in 68%‐85%.17,31 One of these stud‐
ies in 27 children with PWS also performed a combined test (GHRH‐
arginine or GHRH‐pyridostigmine test), which showed a much lower 
prevalence of GHD (15%) than the clonidine and arginine tests.31 As 
studies in adults with PWS have described a higher prevalence of 
GHD after combined stimulation tests, the authors of both studies 
suggested that GHD in PWS might be due to an evolving process, 
with pituitary GH reserve decreasing with age.17,31 Although we did 
not perform GH stimulation tests during childhood before starting 
GH treatment, our data show that, of the 18 children with an IGF‐I 
<−2 SDS at start of GH treatment, all but two patients had normal 
serum IGF‐I levels (>−2 SDS) after cessation of GH at adult height 
attainment. This finding contradicts the hypothesis that GHD might 
become more prevalent with age.
Our data are in line with those of most non‐PWS patients with 
idiopathic childhood‐onset GHD, who have a normal GH response 
when retested as adults.32‐34 The reasons why are unknown, but may 
include a variable GH response to stimulation, GHD being a transient 
condition or GHD being partial, preventing normal growth during 
childhood, but not causing symptoms in adulthood. We cannot, how‐
ever, exclude that GH treatment stimulates GH secretory cells in the 
pituitary and that this GH effect persists, even after GH treatment 
is discontinued. This hypothesis is supported by a recent RCT, which 
showed that one year of placebo in previously GH‐treated young 
adults with PWS did not deteriorate cognitive functioning and might 
suggest that the neurotropic effects of long‐term GH during child‐
hood last into adulthood.35
During the transition period, the body undergoes physical and 
psychological changes that conclude the shift from childhood to 
adulthood. GH seems to play an important role in this transition, as it 
favourably influences body composition, lipid profile and peak bone 
density in adolescents with GHD.36 In PWS, studies have shown a 
deterioration of body composition after cessation of GH treatment, 
while continuing GH after attainment of adult height maintained the 
improved FM and LBM obtained during childhood, supporting the 
presence of clinical GHD.10,11 However, as most adults with PWS do 
not fulfil the consensus criteria for adult GHD, they currently cannot 
be treated with GH after attainment of adult height.
In conclusion, in a large group of previously GH‐treated patients 
with PWS, GH peak levels during a GHRH‐arginine test were low in 
15% of patients, but not one patient fulfilled the criteria for adult 
GHD. These results are against expectations, as several studies have 
shown that GH treatment has positive effects on body composition 
and health profile in adults with PWS.
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